Viking Therapeutics (GB:0VQA)
LSE:0VQA
UK Market

Viking Therapeutics Stock Analysis & Ratings

GB:0VQA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$2.4
VolumeN/A
Average Volume (3M)167.00
Market Cap$185.85M
P/E RatioN/A
Beta2.42
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score9
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0VQA FAQ

What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Viking Therapeutics’s market cap?
    Viking Therapeutics’s market cap is $185.85M.
      What is Viking Therapeutics’s price target?
      The average price target for Viking Therapeutics is $15.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $21.00 ,the lowest forecast is $10.00. The average price target represents 549.46% Increase from the current price of $2.402.
        What do analysts say about Viking Therapeutics?
        Viking Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Viking Therapeutics’s upcoming earnings report date?
          Viking Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 80 days.
            How were Viking Therapeutics’s earnings last quarter?
            Viking Therapeutics released its earnings results on Apr 27, 2022. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.018.
              Is Viking Therapeutics overvalued?
              According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
                Does Viking Therapeutics pay dividends?
                Viking Therapeutics does not currently pay dividends.
                What is Viking Therapeutics’s EPS estimate?
                Viking Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Viking Therapeutics have?
                Viking Therapeutics has 77,370,000 shares outstanding.
                  What happened to Viking Therapeutics’s price movement after its last earnings report?
                  Viking Therapeutics reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went down -4.219%.
                    Which hedge fund is a major shareholder of Viking Therapeutics?
                    Among the largest hedge funds holding Viking Therapeutics’s share is Graham Capital Management, L.P.. It holds Viking Therapeutics’s shares valued at 381K.

                      ---

                      Viking Therapeutics Stock Analysis

                      Smart Score
                      9
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $15.60
                      ▲(549.46% Upside)
                      Strong Buy
                      The Viking Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Viking Therapeutics

                      Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Genfit
                      Intercept Pharma
                      Radius Health
                      Ligand Pharma
                      Johnson & Johnson

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis